Trial Profile
A phase II clinical study to assess efficacy and safety of AV-101 in patients suffering from neuropathic pain
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 02 Jul 2018
Price :
$35
*
At a glance
- Drugs AV 101 (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- 26 Jun 2018 According to a VistaGen Therapeutics media release, FDA authorization to initiate this trial is anticipated in the second half of 2018 and the trial is anticipated to initiate in the first half of 2019.
- 19 Sep 2011 New trial record